PEDIATRICS Vol. 94 No. 1 July 1994, pp. 135
This Article
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Kinsella, J. P.
Right arrow Articles by Abman, S. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kinsella, J. P.
Right arrow Articles by Abman, S. H.

Letter to the Editor

John P. Kinsella MD1 and Steven H. Abman MD1

1 Dept of Pediatrics, Sections of Neonatology and Pulmonary Medicine, The University of Colorado School of Medicine and The Children's Hospital, Denver, CO

We appreciate the thoughtful comments of Drs Gaston and Keith, and share their concerns about potential toxicity associated with new therapies, including nitric oxide (NO). As we have emphasized in several publications, the potential for NO-related toxicity should be of foremost concern to investigators using this experimental drug.1-4 Moreover, the use of inhalational NO therapy must currently be limited to the most critically ill patients, for whom complications associated with conventional therapy are well recognized.